Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1999-07-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.96.15.8603PMID 10411922PMCID PMC17563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The organization of mature T-cell pools.

  2000cited by this paper
• T lymphocyte costimulation mediated by reorganization of membrane microdomains.

  1999cited by this paper
• Costimulatory regulation of T cell function.

  1999cited by this paper
• Linear differentiation of cytotoxic effectors into memory T lymphocytes.

  1999cited by this paper
• CTLA-4-Mediated inhibition of early events of T cell proliferation.

  1999cited by this paper
• Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation.

  1998cited by this paper
• Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28

  1998cited by this paper
• The organization of mature T-cell pools.

  1998cited by this paper
• B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28

  1998cited by this paper
• Secondary but not primary T cell responses are enhanced in CTLA‐4‐deficient CD8+ T cells

  1998cited by this paper
• A receptor/cytoskeletal movement triggered by costimulation during T cell activation.

  1998cited by this paper
• Molecular basis of T cell inactivation by CTLA-4.

  1998cited by this paper
• Allelic Inclusion of T Cell Receptor α Genes Poses an Autoimmune Hazard Due to Low-Level Expression of Autospecific Receptors

  1998cited by this paper
• Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells.

  1998cited by this paper
• Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation.

  1998cited by this paper
• Expression and function of CTLA-4 in Th1 and Th2 cells.

  1998cited by this paper
• Helper T cell differentiation is controlled by the cell cycle.

  1998cited by this paper
• Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.

  1998cited by this paper
• Long-term T cell memory requires the surface expression of self-peptide/major histocompatibility complex molecules.

  1998cited by this paper
• CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.

  1998cited by this paper
• Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance.

  1998cited by this paper
• Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

  1998cited by this paper
• Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction

  1998cited by this paper
• Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors.

  1998cited by this paper
• Co-stimulation in T cell responses.

  1997cited by this paper
• Thymocyte development is normal in CTLA-4-deficient mice.

  1997cited by this paper
• Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

  1997cited by this paper
• Differential requirements for survival and proliferation of CD8 naïve or memory T cells.

  1997cited by this paper
• Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

  1997cited by this paper
• Peripheral T Cell Survival Requires Continual Ligation of the T Cell Receptor to Major Histocompatibility Complex–Encoded Molecules

  1997cited by this paper
• Survival of Mature CD4 T Lymphocytes Is Dependent on Major Histocompatibility Complex Class II–expressing Dendritic Cells

  1997cited by this paper
• Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor‐transgenic CTLA‐4‐deficient mice

  1997cited by this paper
• Human Influence on the Atmospheric Vertical Temperature Structure: Detection and Observations

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses

  1996cited by this paper
• MHC class II molecules are not required for survival of newly generated CD4+ T cells, but affect their long-term life span.

  1996cited by this paper
• Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4

  1996cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• Incomplete T cell receptor V beta allelic exclusion and dual V beta-expressing cells.

  1995cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper
• Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.

  1994cited by this paper
• Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93-103).

  1994cited by this paper
• Activation of naive, memory and effector T cells.

  1994cited by this paper
• Response of naive antigen-specific CD4+ T cells in vitro: characteristics and antigen-presenting cell requirements

  1992cited by this paper
• RAG-1-deficient mice have no mature B and T lymphocytes.

  1992cited by this paper
• Selective development of CD4+ T cells in transgenic mice expressing a class II MHC-restricted antigen receptor

  1989cited by this paper
• T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous α- and β-genes

  1988cited by this paper
• Expression of T-cell receptor alpha-chain genes in transgenic mice

  1988cited by this paper
• T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes.

  1988cited by this paper
• T‐Cell Unresponsiveness in vivo and in vitro: Fine Specificity of Induction and Molecular Characterization of the Unresponsive State

  1987cited by this paper
• Ia-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysozyme-specific T cells.

  1985cited by this paper

• Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.

  2026cites this paper
• Dissection of the trans-endocytosis and signal inhibition functions of CTLA-4 through the study of a disease-associated Y139C mutation

  2025cites this paper
• Hypobaric Conditions in Cabin Altitude Restricted Aeromedical Evacuation Induce Systemic Inflammation Following Porcine Traumatic Brain Injury.

  2025cites this paper
• Hypobaria During Aeromedical Evacuation and Systemic Inflammation after Porcine Traumatic Brain Injury.

  2024cites this paper
• Role of Immune Cells and Immunotherapy in Multiple Myeloma

  2024cites this paper
• Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

  2023cites this paper
• Turning up the heat: CTLA4 blockade in urothelial cancer

  2023cites this paper
• Risk factors for immune-related adverse events: what have we learned and what lies ahead?

  2021cites this paper
• GWAS for autoimmune Addison’s disease identifies multiple risk loci and highlights AIRE in disease susceptibility

  2021cites this paper
• Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases

  2021influential citation
• A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma

  2021cites this paper
• CTLA-4: From mechanism to autoimmune therapy.

  2020cites this paper
• Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity

  2020cites this paper
• Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques

  2019cites this paper
• Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis

  2019cites this paper
• Co-signal Molecules in T-Cell Activation : Historical Overview and Perspective.

  2019cites this paper
• Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2018cites this paper
• Neonatal influenza‐specific effector CTLs retain elevated CD31 levels at the site of infection and have decreased IFN‐γ production

  2018cites this paper
• Human CD8+HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+Foxp3+ Cells, Suppress Immune Responses via PD-1/PD-L1 Axis

  2018cites this paper
• Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

  2018cites this paper
• Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses

  2017cites this paper
• CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation.

  2017cites this paper
• Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

  2017cites this paper
• The molecular understanding of cancer: from the unspeakable illness to a curable disease

  2017cites this paper
• Prognostic value of PDCD-1 and CTLA-4 in ovarian cancer patients

  2016cites this paper
• Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

  2016influential citation
• The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.

  2016cites this paper
• Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+ T Cell Priming To Promote Memory Formation and Metabolic Readiness

  2015cites this paper
• Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.

  2015cites this paper
• Cytokine regulation of immune tolerance

  2014cites this paper
• Identification of SAP as a CTLA-4 Binding Molecule : a Role of SAP in CTLA-4 Signaling Proposed

  2014cites this paper
• Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer

  2014cites this paper
• Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?

  2014cites this paper
• Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab

  2013cites this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cites this paper
• Immunotherapy for Renal Cell Carcinoma

  2013cites this paper
• Study of immunomics and immune regulation in ovarian cancer

  2013cites this paper
• At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy

  2013cites this paper
• Cancer Immunotherapy

  2013cites this paper
• Immune co-signaling to treat cancer

  2013cites this paper
• cytotoxic T lymphocytes in vivo B7-CTLA4 interaction promotes cognate destruction of tumor cells by

  2013cites this paper
• Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans

  2012cites this paper
• Trypanosoma cruzi Infection with the Intracellular Protozoan CTLA-4 Blockage Increases Resistance to

  2012cites this paper
• HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients

  2012cites this paper
• Immunotherapy for melanoma

  2012cites this paper
• Modulation of CTLA-4 and GITR for cancer immunotherapy.

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Immune Regulatory Antibodies: Are They the Next Advance?

  2010cites this paper
• Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

  2010cites this paper
• Adoptive Therapy Using Antigen-Specific T-Cell Clones

  2010cites this paper
• CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms

  2010cites this paper
• Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

  2010cites this paper
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cites this paper
• Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation

  2009cites this paper
• Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis

  2009cites this paper
• Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

  2009cites this paper
• Intracellular concentrations of Ca2+ modulate the strength of signal and alter the outcomes of cytotoxic T‐lymphocyte antigen‐4 (CD152)–CD80/CD86 interactions in CD4+ T lymphocytes

  2009cites this paper
• CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance

  2008cites this paper
• Costimulation blockade: towards clinical application.

  2008cites this paper
• New Approaches to Antibody Therapy

  2008cites this paper
• Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

  2008cites this paper
• Development and validation of stabilized whole blood samples expressing T-cell activation markers as quality control reference material

  2008cites this paper
• Costimulation blockade in transplantation of nerve allografts: long‐term effects

  2008cites this paper
• Pitfalls or Promise in Prostate Cancer Immunotherapy—Which Is Winning?

  2008cites this paper
• Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?

  2008cites this paper
• Drug Development in Cancer Medicine: Challenges for Targeted Approaches

  2008cites this paper
• Checkpoint blockade in cancer immunotherapy.

  2007cites this paper
• Checkpoint Blockade and Combinatorial Immunotherapies

  2007cites this paper
• The Extended CD 28 : B 7 Immunoglobulin Superfamily

  2007cites this paper
• Progress toward antibody-induced transplantation tolerance.

  2007cites this paper
• Pivotal Advance: CTLA‐4+ T cells exhibit normal antiviral functions during acute viral infection

  2007cites this paper
• Emerging role of immunotherapy in the management of prostate cancer.

  2007cites this paper
• T cell–directed therapies: lessons learned and future prospects

  2007cites this paper
• CTLA-4 Ablation and Interleukin-12–Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T Lymphocytes

  2007cites this paper
• T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.

  2007cites this paper
• Induction of autoimmune disease in CTLA-4−/− mice depends on a specific CD28 motif that is required for in vivo costimulation

  2007cites this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cites this paper
• Immunologic targeting: how to channel a minimal response for maximal outcome

  2006cites this paper
• A New Look at Blockade of T‐cell Costimulation: A Therapeutic Strategy for Long‐term Maintenance Immunosuppression

  2006cites this paper
• A molecular perspective of CTLA-4 function.

  2006cites this paper
• Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression

  2006cites this paper
• CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

  2006cites this paper
• CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism1

  2006cites this paper
• The Role of Membrane Lipids in the Regulation of Immune Cell Activity

  2006cites this paper
• Responses through a CD 28B 7-Dependent CTLA-4 Overexpression Inhibits T Cell

  2006cites this paper
• Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

  2006cites this paper
• Lack of Intrinsic CTLA-4 Expression Has Minimal Effect on Regulation of Antiviral T-Cell Immunity

  2006cites this paper
• Targeting Extracellular Molecules in Prostate Cancer—Mechanisms to Inhibit Entry into the Cell-Signaling Abyss

  2006cites this paper
• Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily

  2005cites this paper
• Induction of T-Cell Apoptosis in Rats by Genetically Engineered Glioma Cells Expressing Granulocyte-Macrophage Colony-Stimulating Factor and B7.1

  2005cites this paper
• Cell Reactivity in Adaptive Tolerance Production but Is Not Required for Tuning T T Cell Proliferation and Cytokine +CTLA-4 Engagement Acts as a Brake on CD4

  2004cites this paper
• CTLA-4 Engagement Acts as a Brake on CD4+ T Cell Proliferation and Cytokine Production but Is Not Required for Tuning T Cell Reactivity in Adaptive Tolerance

  2004cites this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cites this paper
• CTLA-4 Blockage Increases Resistance to Infection with the Intracellular Protozoan Trypanosoma cruzi1

  2004cites this paper
• T cell costimulation in anti-tumor immunity and autoimmunity.

  2004cites this paper
• 8 – GENES AND GENETICS OF MURINE LUPUS

  2004cites this paper
• Accentuating Tumor Immunity Through Costimulation

  2004cites this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cites this paper
• CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls.

  2003cites this paper
• Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.

  2003cites this paper